Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555750 · ClinicalTrials.gov registry record · NA
Sleep Loss and Mechanisms of Impaired Glucose Metabolism
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00555750 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants.
The verdict
NCT00555750, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S. Food and Drug Administration (FDA) for sale for the treatment of insomnia. It is marketed in the United States as LUNESTA. Main Hypothesis: Primary insomnia is associated with impairments of glucose metabolism that can be reversed by two months of eszopiclone for the primary insomnia
Interventions
- DRUG placebo
- DRUG eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555750
The ClinicalTrials.gov registry entry for NCT00555750 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00555750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00555750 about?
NCT00555750 is a clinical study titled "Sleep Loss and Mechanisms of Impaired Glucose Metabolism". The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S. Food and Drug Administration (FDA) for sale for the treatment of insomnia. It is marketed in the United States as ...
What is the current status of trial NCT00555750?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2006-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00555750?
The interventions under investigation include: placebo (DRUG), eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00555750?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.